We understand the importance of timely public drug coverage for Canadian patients. That’s why we’re introducing new and refreshed negotiation processes.
Full details of our Early Negotiation Process (ENP) and our Targeted Negotiation Process (TNP) are now available for review, along with an online survey to gather your feedback.
The ENP has been designed for cancer drugs being reviewed under the Project Orbis initiative. This process aims to reduce negotiation times by several months by starting negotiations before a final health technology assessment reimbursement recommendation has been issued. The intent is to have completed negotiations by the time final reimbursement recommendations are published.
The TNP is a pathway designed for non-complex drug negotiations, including drugs comparable to others already available in the market. We’re introducing revisions to our TNP, which is a streamlined process that’s been available as a negotiation option since 2021.